Many object to embryo selection because they mistakenly believe it involves altering genes. In reality, the technology simply reveals information about natural genetic variations already present in IVF embryos, allowing parents to choose, not tinker.

The controversy and business opportunity in polygenic embryo selection lie in interpreting genetic data, not in the physical sequencing. Companies are competing on the quality and scope of their predictive models for health and traits, which they apply to data from established lab processes.

The burgeoning field of polygenic risk scores is dangerously unregulated, with some well-capitalized companies selling products that are 'no better than chance.' The key differentiator is rigorous, public validation of their predictive models, especially across ancestries, a step many firms skip.

In the U.S., support for embryo screening for disease is nearly double that for intelligence, while in Singapore, support is equal. This gap is attributed to Western taboos from WWII-era eugenics, creating a moral distinction between selecting against negative traits and for positive ones that is less pronounced elsewhere.

The predictive power of embryo screening can be validated without controversial longitudinal studies on children. By testing if models can accurately predict trait differences between adult siblings using only their DNA, companies can prove efficacy for embryos, who are essentially unrealized siblings.

A new innovation allows companies to construct an embryo's entire genome using raw data from a standard Down syndrome test. This means parents can get comprehensive polygenic reports without needing explicit approval from clinics or doctors, effectively democratizing access and removing traditional medical gatekeepers.

Standard IVF practice involves a doctor visually selecting the embryo that appears most "normally shaped." This is already a form of selection. Polygenic screening simply replaces this subjective "eyeballing" method with quantitative genetic data for a more informed choice, making it an evolution, not a revolution.

Polygenic embryo screening, while controversial, presents a clear economic value proposition. A $3,500 test from Genomic Prediction that lowers Type 2 Diabetes risk by 12% implies that avoiding the disease is worth over $27,000. This reframes the service from 'designer babies' to a rational financial decision for parents.

Despite decoding his own six-billion-letter genome, Dr. Venter emphasizes that our ability to interpret this data meaningfully is in its infancy. He points out that even for a simple trait like eye color, the genetic code doesn't provide 100% certainty, highlighting the naivety of relying on single genes to predict complex traits or diseases.